Most of this week’s news came from people with the standing to say no. FDA put its expectations for surgical robots in writing and a Class I label on a heart-pump controller, an advisory panel split over the first multi-cancer blood test, an activist told Cooper’s board to find a new CEO, and Fresenius decided the cheap end of China wasn’t worth the factory. Hospitals, for their part, were told to keep running the recalled Impella controllers and just switch to the backup when the alarm goes off.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🤖 FDA writes down what it wants from surgical robots
CDRH issued draft guidance on premarket submissions for robotically-assisted surgical devices, covering non-clinical testing, clinical data and labeling expectations. Comments close November 24 under docket FDA-2026-N-9505. The agency also scheduled a public workshop on benefit-risk for robotic devices with autonomous or remote teleoperation features. The timing matters: a half-dozen platforms are mid-clearance and have been guessing at the evidence bar. A written bar is easier to clear than an inferred one, and harder to argue with.
FDA
2. 🧬 Advisers back the first multi-cancer blood test, barely
The Molecular and Clinical Genetics Panel voted 7-2-1 that Galleri’s benefits outweigh its risks, was unanimous on safety, and split 6-4 on effectiveness. GRAIL’s PMA rests on PATHFINDER 2 and NHS-Galleri, which together found four to seven times more cancers than standard screening alone. FDA decides in the coming months and is not bound by the vote. That 6-4 effectiveness margin is the number every MCED developer behind Grail should be reading.
The ASCO Post
3. ❤️ Impella controller recall goes Class I after three deaths
FDA classified Abiomed’s removal of Automated Impella Controllers as Class I, citing purge-cassette recognition failures that trigger alarms and delay circulatory support. Thirty-seven serious injuries and three deaths were reported as of August 17; Abiomed notified customers August 12. Hospitals keep using existing units and fall back to spares while service replaces the part. A component-level defect on a market-leading platform, managed as a service call rather than a pull.
FDA
📋 You probably already know which part of your commercial case is weakest.
Most teams do. What’s harder is knowing what it’ll cost you at your next milestone, and what to do about it first. The free Commercial Readiness Check from RŌG Health takes two minutes and scores your case across five dimensions — buyer, evidence, economics, adoption, and capability — then tells you where you’re exposed and what to settle before you go.
Sponsored by RŌG Health
4. 💼 Jana tells Cooper’s board to sell divisions and replace the CEO
Jana Partners sent a letter pressing Cooper Companies to divest businesses, replace CEO Albert White and install a new chair, after the board unanimously voted to keep CooperSurgical. Cooper cut 2026 revenue guidance to $4.23–$4.25 billion; CooperVision’s quarter was flat at $717.0 million. Browning West has pushed a pure-play vision case since November 2025. A failed process plus lowered guidance is the combination that turns one activist letter into two.
MassDevice
5. 📉 Adagio cuts 25 of 43 employees and opens a strategic review
Adagio Medical laid off 25 of its 43 full-time staff, booked $1.3 million in severance, and began exploring a sale, merger or acquisition. It held roughly $7.7 million in cash mid-year and faces Nasdaq delisting over the $2.5 million equity minimum. Shares closed at 23 cents against a $2.58 52-week high. The vCLAS ventricular cryoablation system is still sitting at FDA on a PMA — the asset outlived the company’s ability to fund it.
Fierce Biotech
6. 🌏 Fresenius walks out of the cheap end of China
Fresenius Medical Care will stop making and selling the 4008A hemodialysis system in China and exit the country’s peritoneal dialysis business, taking about €110 million in impairment, scrappage and termination costs in Q3. China is 6–7% of Care Enablement revenue. The company is betting on the 5008S and multiFiltratePRO instead. The 4008A launched in 2019 as an emerging-market value play; value turned out to be the one position that does not pay.
Fresenius Medical Care
7. 🩸 First sirolimus drug-eluting balloon clears FDA
FDA approved Cordis’s Selution SLR for coronary in-stent restenosis on September 21, the first sirolimus-coated balloon in the US and only the second drug-coated balloon overall after Boston Scientific’s Agent in 2024. SELUTION4ISR showed noninferiority to standard care on one-year target lesion failure. Cordis also finished enrolling 960 patients in SELUTION4DeNovo for small-vessel de novo lesions — the indication where the balloon-versus-stent argument actually gets settled.
TCTMD
8. 🧪 Siemens Healthineers and Novo go looking for liver disease together
The two are partnering on US awareness and triage for MASLD and MASH, built around Siemens’s ELF blood test for advanced fibrosis risk — no biopsy, no specialized imaging. Roughly a quarter of US adults have MASLD and most do not know it. Novo has Wegovy approved in noncirrhotic MASH; Madrigal’s Rezdiffra opened the category in 2024. Pharma paying to find the patients is the closest thing diagnostics gets to a free sales force.
Fierce Biotech
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.